title: [Recent progress in the "fibrinogen hypothesis"].
abstract: Several clinical and epidemiological studies have demonstrated that a high level of plasma fibrinogen is an independent risk factor for coronary, cerebral and peripheral artery disease. The role of fibrinogen in cardiovascular diseases is mainly due to thrombotic complications in advanced stages of the atherothrombotic disease. However, fibrinogen also plays an active role in the initiation and development of atheromatous plaques. The relations between fibrinogen and ischemic cardiopathies, other vasculopathies and diabetes mellitus are discussed. The controversial effects of statins on fibrinogen are also described.
authors.affiliation: Service de Cardiologie, C.H.U. Tivoli, U.L.B.
authors.forename: P
authors.initials: P
authors.lastname: Lefebvre
authors.forename: Th
authors.initials: T
authors.lastname: Ledent
authors.forename: J
authors.initials: J
authors.lastname: Ducobu
mesh_terms: D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D048909:Diabetes Complications; D005340:Fibrinogen / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005340:Fibrinogen